Psoriasis Clinical Trial
A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
Summary
To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque psoriasis and to document the same using sequential photographic images.
Eligibility Criteria
Inclusion Criteria:
Present with chronic moderate-to-severe plaque psoriasis based on a confirmed (by a dermatologist) diagnosis of chronic plaque psoriasis for at least 6 months prior to baseline
Active psoriatic skin lesions of plaque psoriasis (Ps)
Are a candidate for phototherapy and/or systemic therapy
Men must agree to use a reliable method of birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment
Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment
Exclusion Criteria:
Are unable to commit to the photography schedule for the duration of the study
Have participated in any study with interleukin 17 (IL-17) or (IL-23) antagonists, including ixekizumab
Serious disorder or illness other than psoriasis
Serious infection within the last 3 months
Breastfeeding or nursing (lactating) women
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10029, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.